Advertisement

Topics

Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD

11:07 EDT 21 Jun 2017 | BioPortfolio Report Blog

Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR Pipeline Review, H1 2017

Summary

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 16 Pipeline Review, H1 2017'; Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulindependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT3, and NT4.

The report 'Tumor Necrosis Factor Receptor Superfamily Member 16 Pipeline Review, H1 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in PreRegistration, Phase II and Preclinical stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System, Dermatology, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Pain, Corneal Ulcer Ulcerative Keratitis/ Eyesore, HIV Related Neurological Diseases, Huntington Disease, Keratoconjunctivitis sicca Dry Eye, OpenAngle Glaucoma, Osteoarthritis, Persistent Corneal Epithelial Defects, Retinitis Pigmentosa Retinitis, Spinal Cord Injury, Traumatic Brain Injury and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR
The report reviews Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics and enlists all their major and minor projects
The report assesses Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD

NEXT ARTICLE

More From BioPortfolio on "Tumor Necrosis Factor Receptor Superfamily Member 16 Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR Pipeline Review, H1 2017 [Updated: 20062017] Prices from USD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...